The role of IL-2 in the activation and expansion of regulatory T-cells and the development of experimental autoimmune encephalomyelitis

Immunobiology

Volumn 218, Issue 4, 2013, Pages 674-682

  Rouse, Michael ^a   Nagarkatti, Mitzi ^a   Nagarkatti, Prakash S ^a  

^a UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Experimental autoimmune encephalomyelitis (EAE); Multiple sclerosis (MS); Recombinant interleukin 2 (rIL 2); Regulatory T cells (Treg); Th17 cells

Indexed keywords

MYELIN OLIGODENDROCYTE GLYCOPROTEIN; RECOMBINANT INTERLEUKIN 2;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; CELL EXPANSION; CELL INFILTRATION; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HISTOPATHOLOGY; LYMPHOCYTE ACTIVATION; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SPINAL CORD; TH17 CELL; TISSUE PRESERVATION;

ANIMALS; ANTINEOPLASTIC AGENTS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; HUMANS; INTERLEUKIN-2; MICE; MULTIPLE SCLEROSIS; MYELIN-OLIGODENDROCYTE GLYCOPROTEIN; PEPTIDE FRAGMENTS; SPINAL CORD; T-LYMPHOCYTES, REGULATORY; TH17 CELLS;

EID: 84875246213     PISSN: 01712985     EISSN: 18783279     Source Type: Journal    
DOI: 10.1016/j.imbio.2012.08.269     Document Type: Article

References (45)

1. Aharoni R., Saada R., Eilam R., Hayardeny L., Sela M., Arnon R. Oral treatment with laquinimod augments regulatory T-cells and brain-derived neurotrophic factor expression and reduces injury in the CNS of mice with experimental autoimmune encephalomyelitis. J. Neuroimmunol. 2012, (Ahead of Print).
2. Alexander J.S., Harris M.K., Wells S.R., Mills G., Chalamidas K., Ganta V.C., McGee J., Jennings M.H., Gonzalez-Toledo E., Minagar A. Alterations in serum MMP-8, MMP-9, IL-12p40 and IL-23 in multiple sclerosis patients treated with interferon-beta1b. Mult. Scler. 2010, 16:801-809.
3. Ando D.G., Clayton J., Kono D., Urban J.L., Sercarz E.E. Encephalitogenic T cells in the B10.PL model of experimental allergic encephalomyelitis (EAE) are of the Th-1 lymphokine subtype. Cell. Immunol. 1989, 124:132-143.
4. Andrus L., Granelli-Piperno A., Reich E. Cytotoxic T cells both produce and respond to interleukin 2. J. Exp. Med. 1984, 159(2):647-652.
5. Axtell R.C., de Jong B.A., Boniface K., van der Voort L.F., Bhat R., De Sarno P., Naves R., Han M., Zhong F., Castellanos J.G., Mair R., Christakos A., Kolkowitz I., Katz L., Killestein J., Polman C.H., de Waal Malefyt R., Steinman L., Raman C. T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis. Nat. Med. 2010, 16:406-412.
6. Balsamo M., Vermi W., Parodi M., Pietra G., Manzini C., Queirolo P., Lonardi S., Augugliaro R., Moretta A., Facchetti F., Moretta L., Mingari M.C., Vitale M. Melanoma cells become resistant to NK-cell-mediated killing when exposed to NK-cell numbers compatible with NK-cell infiltration in the tumor. Eur. J. Immunol. 2012, (Ahead of Print).
7. Baluna R., Vitetta E.S. Vascular leak syndrome: a side effect of immunotherapy. Immunopharmacology 1997, 37:117-132.
8. Beadling C., Johnson K.W., Smith K.A. Isolation of interleukin 2-induced immediate-early genes. Proc. Natl. Acad. Sci. U. S. A. 1993, 90(7):2719-2723.
9. Beadling C.B., Smith K.A. DNA array analysis of interleukin-2-regulated immediate/early genes. Med. Immunol. 2002, 1(1):2.
10. Bettelli E., Sullivan B., Szabo S.J., Sobel R.A., Glimcher L.H., Kuchroo V.K. Loss of T-bet, but not STAT1, prevents the development of experimental autoimmune encephalomyelitis. J. Exp. Med. 2004, 200:79-87.
11. Bjerg L., Brosbøl-Ravnborg A., Tørring C., Dige A., Bundgaard B., Petersen T., Höllsberg P. Altered frequency of T regulatory cells is associated with disability status in relapsing-remitting multiple sclerosis patients. J. Neuroimmunol. 2012, 249(1-2):76-82.
12. Cerdan C., Martin Y., Courcoul M., Brailly H., Mawas C., Birg F., Olive D. Prolonged IL-2 Receptor α/CD25 expression after T-cell activation via the adhesion molecules CD2 and CD28. Demonstration of combined transcriptional and post-transcriptional regulation. J. Immunol. 1992, 149(7):2255-2261.
13. Chen Y., Langrish C.L., McKenzie B., Joyce-Shaikh B., Stumhofer J.S., McClanahan T., Blumenschein W., Churakovsa T., Low J., Presta L., Hunter C.A., Kastelein R.A., Cua D.J. Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis. J. Clin. Invest. 2006, 116:1317-1326.
14. Chitnis T., Najafian N., Benou C., Salama A.D., Grusby M.J., Sayegh M.H., Khoury S.J. Effect of targeted disruption of STAT4 and STAT6 on the induction of experimental autoimmune encephalomyelitis. J. Clin. Invest. 2001, 108:739-747.
15. Compston A., Coles A. Multiple sclerosis. Lancet 2002, 359(9313):1221-1231.
16. Fransson M., Piras E., Burman J., Nilsson B., Essand M., Lu B., Harris R.A., Magnusson P.U., Brittebo E., Loskog A.S. CAR/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery. J. Neuroinflamm. 2012, 9(1):112.
17. Gallagher D.C., Bhatt R.S., Parikh S.M., Patel P., Seery V., McDermott D.F., Atkins M.B., Sukhatme V.P. Angiopoietin 2 is a potential mediator of high-dose interleukin 2-induced vascular leak. Clin. Cancer Res. 2007, 13(7):2115-2120.
18. Gocke A.R., Cravens P.D., Ben L., Hussain R.Z., Northrop S.C., Racke M.K., Lovett-Racke A.E. T-bet regulates the fate of Th1 and Th17 lymphocytes in autoimmunity. J. Immunol. 2007, 178:1341-1348.
19. Guan H., Nagarkatti P.S., Nagarkatti M. CD44 Reciprocally regulates the differentiation of encephalitogenic Th1/Th17 and Th2/regulatory T cells through epigenetic modulation involving DNA methylation of cytokine gene promoters, thereby controlling the development of experimental autoimmune encephalomyelitis. J. Immunol. 2011, 186(12):6955-6964.
20. Guan H., Singh N.P., Singh U.P., Nagarkatti P.S., Nagarkatti M. Resveratrol prevents endothelial cells injury in high-dose interleukin-2 therapy against melanoma. PLoS ONE 2012, 7(4):e35650.
21. Hao J., Campagnolo D., Liu R., Piao W., Shi S., Hu B., Xiang R., Zhou Q., Vollmer T., Van Kaer L., La Cava A., Shi F.D. Interleukin-2/interleukin-2 antibody therapy induces target organ natural killer cells that inhibit central nervous system inflammation. Ann. Neurol. 2011, 69(4):721-734.
22. Huang D., Han Y., Rani M.R., Glabinski A., Trebst C., Sørensen T., Tani M., Wang J., Chien P., O'Bryan S., Bielecki B., Zhou Z.L., Majumder S., Ransohoff R.M. Chemokines and chemokine receptors in inflammation of the nervous system: manifold roles and exquisite regulation. Immunol. Rev. 2000, 177:52-67.
23. Jeon E.J., Yoon B.Y., Lim J.Y., Oh H.J., Park H.S., Park M.J., Lim M.A., Park M.K., Kim K.W., Cho M.L., Cho S.G. Adoptive transfer of all-trans-retinal-induced regulatory T cells ameliorates experimental autoimmune arthritis in an interferon-gamma knockout model. Autoimmunity 2012, (Ahead of Print).
24. reg cells fit. Nat. Immunol. 2005, 6:1071-1072.
25. Langrish C.L., Chen Y., Blumenschein M., Mattson J., Basham B., Sedgwick J.D., McClanahan T., Kastelein R.A., Cua D.J. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med. 2005, 201:233-240.
26. Lovett-Racke A.E., Rocchini A.E., Choy J., Northrop S.C., Hussain R.Z., Ratts R.B., Sikder D., Racke M.K. Silencing T-bet defines critical role in the differentiation of autoreactive T lymphocytes. Immunity 2004, 21:719-731.
27. Malek T.R. T helper cells, IL-2 and the generation of cytotoxic T-cell responses. Trends Immunol. 2002, 23(10):465-467.
28. McDonald A.H., Swanborg R.H. Antigen-specific inhibition of immune interferon production by suppressor cells of autoimmune encephalomyelitis. J. Immunol. 1988, 140:1132-1138.
29. Melencio L., McKallip R.J., Guan H., Ramakrishnan R., Jain R., Nagarkatti P.S., Nagarkatti M. Role of CD4(+)CD25(+) T regulatory cells in IL-2-induced vascular leak. Int. Immunol. 2006, 18(10):1461-1471.
30. Morisaki T., Umebayashi M., Kiyota A., Koya N., Tanaka H., Onishi H., Katano M. Combining cetuximab with killer lymphocytes synergistically inhibits human cholangiocarcinoma cells in vitro. Anticancer Res. 2012, 32(6):2249-2256.
31. Nath N., Prasad R., Giri S., Singh A.K., Singh I. T-bet is essential for the progression of experimental autoimmune encephalomyelitis. Immunology 2006, 118:384-391.
32. Pettinelli C.B., McFarlin D.E. Adoptive transfer of experimental allergic encephalomyelitis in SJL/J mice after in vitro activation of lymph node cells by myelin basic protein: requirement for Lyt1+ 2-T lymphocytes. J. Immunol. 1981, 127:1420-1423.
33. Rosati G. The prevalence of multiple sclerosis in the world: an update. Neurol. Sci. 2011, 22(2):117-139.
34. Rosenburg S.A. Interleukin 2 for patients with renal cancer. Nat. Clin. Pract. Oncol. 2007, 4:497.
35. Sakaguchi S., Sakaguchi N., Asano M., Itoh M., Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 1995, 155(3):1151-1164.
36. Singh N.P., Hegde V.L., Hofseth L.J., Nagarkatti M., Nagarkatti P. Resveratrol (trans-3,5,4'-trihydroxystilbene) ameliorates experimental allergic encephalomyelitis, primarily via induction of apoptosis in T cells involving activation of aryl hydrocarbon receptor and estrogen receptor. Mol. Pharmacol. 2007, 72(6):1508-1521.
37. Sojka D.K., Huang Y.H., Fowell F.J. Mechanisms of regulatory T-cell suppression - a diverse arsenal for a moving target. Immunology 2008, 124(1):13-22.
38. Stern J., Smith K.A. Interleukin-2 induction of T-cell G1 progression and c-myb expression. Science 1986, 233(4760):203-206.
39. Thornton A.M., Donovan E.E., Piccirillo C.A., Shevach E.M. Cutting edge: IL-2 is critically required for the in vitro activation of CD4+CD25+ T cell suppressor function. J. Immunol. 2004, 172(11):6519-6523.
40. Thornton A.M., Shevach E.M. CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J. Exp. Med. 1998, 188(2):287-296.
41. Tran G.T., Hodgkinson S.J., Carter N.M., Verma N.D., Plain K.M., Boyd R., Robinson C.M., Nomura M., Killingsworth M., Hall B.M. IL-5 promotes induction of antigen-specific CD4+CD25+ T regulatory cells that suppress autoimmunity. Blood 2012, 119(19):4441-4450.
42. Veenstra R.G., Taylor P.A., Zhou Q., Panoskaltsis-Mortari A., Hirashima M., Flynn R., Liu D., Anderson A.C., Strom T.B., Kuchroo V.K., Blazar B.R. Contrasting acute graft-versus-host-disease effects of Tim-3/galectin-9 pathway blockade dependent upon the presence of donor regulatory T cells. Blood 2012, (Ahead of Print).
43. Waldburger K.E., Hastings R.C., Schaub R.G., Goldman S.L., Leonard J.P. Adoptive transfer of experimental allergic encephalomyelitis after in vitro treatment with recombinant murine interleukin-12. Preferential expansion of interferon-gamma-producing cells and increased expression of macrophage-associated inducible nitric oxide synthase as immunomodulatory mechanisms. Am. J. Pathol. 1996, 148:375-382.
44. Yura M., Takahashi I., Serada M., Koshio T., Nakagami K., Yuki Y., Kiyono H. Role of MOG-stimulated Th1 type "light up" (GFP+) CD4+ T cells for the development of experimental autoimmune encephalomyelitis (EAE). J. Autoimmun. 2001, 17:17-25.
45. Zhou J., Nagarkatti P., Zhong Y., Nagarkatti M. Immune modulation by chondroitin sulfate and its degraded disaccharide product in the development of an experimental model of multiple sclerosis. J. Neuroimmunol. 2010, 223(1-2):55-64.